Louise Boulet
TransCanada (Canada)(CA)Merck Canada Inc. (Canada)(CA)
Publications by Year
Research Areas
Phosphodiesterase function and regulation, Asthma and respiratory diseases, Cholinesterase and Neurodegenerative Diseases, Mitochondrial Function and Pathology, RNA and protein synthesis mechanisms
Most-Cited Works
- Distribution and threshold expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF).(1992)
- → Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors(2007)128 cited
- → Deletion of Microsomal Prostaglandin E2 (PGE2) Synthase-1 Reduces Inducible and Basal PGE2 Production and Alters the Gastric Prostanoid Profile(2004)119 cited
- → Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey(2001)79 cited
- → Optimization of a Tertiary Alcohol Series of Phosphodiesterase-4 (PDE4) Inhibitors: Structure−Activity Relationship Related to PDE4 Inhibition and Human Ether-a-go-go Related Gene Potassium Channel Binding Affinity(2003)66 cited
- → Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors(2009)61 cited
- → Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure–activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor(2005)30 cited
- → Mistranslation in twelve Escherichia coli ribosomal proteins. Cysteine misincorporation at neutral amino acid residues other than tryptophan(1987)29 cited
- → Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-α formation with phosphodiesterase 4 (PDE4) selective inhibitors(2002)27 cited
- → [40] Use of myoblast cultures to study mitochondrial myopathies(1996)25 cited